Sluggish EUR/USD rebound reflects a slower distribution of both Recovery Funds and covid vaccines. Economists at Westpac believe the 1.1950-1.2350 range is likely to persist into the European Central Bank (ECB) meeting on Thursday, March 11.
“The EU’s covid vaccine rollout has suffered several logistic and bureaucratic obstacles. Although the total administered vaccines across the region now total almost 35 M, this is quite a shortfall compared to early hopes and is decidedly less than UK (>21 M) and US (>85 M).”
“Regional lockdown restrictions may be on the cusp of being relaxed, but there are growing concerns over the persistence of new COVID-19 cases as new variants take hold. The economic consequence is a potential delay in recoveries which could undermine the optimism which had been featured in recent PMIs.”
“The ECB has underscored that it will maintain PEPP flexibility and that it has further policy tools to provide support if needed. This may well be a feature as the ECB meets next week.”
“EUR/USD is likely to remain contained within an effective 1.1950-1.2350 range.”
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.